News & Analysis on Clinical Trial Services & Contract Research And Development
By Dan Stanton
- Last updated on
To San Francisco, US, next and Adheron Therapeutics has announced the appointments of Robert Baltera (left) and Hari Kumar (right) to serve as executive chairman of the board and CEO, respectively.
Both Baltera and Kumar come from Amira Pharmaceuticals, which was recently acquired by Bristol Myers Squibb for an upfront payment of $325M.
Kumar said: “I am deeply impressed by the innovative technology that we are developing [Cadherin-11] and I look forward to advancing it to the next level.”
Baltera added: “Cadherin-11 is a very promising technology, which I am confident will be applied in various areas of high unmet medical need. I am pleased to lead Adheron and I am confident we will see exciting results.”